




---

# Vaccine Virtual Days 2021



**Translation available**

All sessions will be in English but will feature live translation available in the following languages:













Live sessions will also be recorded and made available on-demand. On-demand offering will include the above language versions.

You will be able to download a Certificate of Attendance after each session.

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK has approved this event/course for Continuous Professional Development (CPD - 10 maximum).




Please note that depending on your country regulations you may not be able to participate to each session.

**Sessions labelled with the following icons may be of interest to:**


	Paediatricians		Vaccine researchers
	General practitioners		Public health experts
	Obstetricians and gynaecologists		Immunologists
	Infectious disease specialists		Pharmacists
	Vaccinators		Nurses

Not yet registered? Register [here!](#)

**DAY 1, 27th April, 13:00 – 19:00 CEST (GMT+2 Belgium)**

Session	Duration	Session Description	Speakers	
13:00-13:05	<b><u>Introduction day 1</u></b>	5min	Introduction	Mary Slack (UK)
13:05-13:20	<b><u>Keynote</u></b>	15min	Bats: good or bad fortune? Questions for Lin-Fa Wang part 1	Lin - Fa Wang (Singapore) Philippe Buchy (Singapore)
13:20-14:50	<b><u>The COVID vaccine roll-out experience, a world tour</u></b> 	90min	- Introduction 10 min presentation from speakers around the world on the current status and overall experience of the COVID vaccine rollout, including aspects such as: - Epidemiological surveillance, - Challenges of vaccine implementation, - Vaccine uptake and coverage, real world evidence Session will be concluded by a round table / Q&A with the attending speakers.	<b>Chair:</b> <b>Paolo Bonanni (Italy)</b> Ran Balicer (Israel) Shamez Ladhani (UK) Shabir Madhi (South Africa) Leyla Namazova - Baranova (Russia) LJ Tan (US) Sanne Wendes (Switzerland)
14:50-15:00	Transfer break	10min		
15:00-16:00	<b><u>Adult vaccination: Not another casualty of the pandemic?</u></b> 	60min	- Introduction Panel discussion followed by Q&A: 1. What we've seen going into the pandemic and what we are seeing coming out 2. Perspective from Asia on adult vaccination in the context of COVID 3. The challenges and learnings from US pharmacy vaccination during COVID - Q&A	<b>Chair:</b> <b>LJ Tan (US)</b> Jane Barratt (Canada) John Tam (Hong Kong) Mitchel Rothholz (US)
16:00-16:20	BREAK	20min		
16:20-17:20	<b><u>Vaccine confidence</u></b> 	60min	- Introduction Presentations followed by a roundtable with Q&A: 1. Vaccine confidence in times of uncertainty 2. #TEAMHALO: Moving beyond correcting misinformation: what is the role of social media in addressing vaccine confidence? 3. Restoring trust in vaccines during times of uncertainty - Q&A	<b>Chair:</b> <b>Emilie Karafillakis (UK)</b> Heidi Larson (UK) Nighat Arif (UK) Rebecca Christopher (US) Ayoade Olatunbosun -Alakija (Nigeria)


17:20-17:30	Transfer break	10min		
-------------	----------------	-------	--	--

	Session	Duration	Session Description	Speakers
17:30-19:00	<p><b><u>Immunization agenda 2030 - reach all for a lifetime</u></b></p> 	90min	<p>Presentations followed by roundtable discussion:</p> <p>Keynote: UNICEF Immunization Agenda 2030 - A Global Strategy To Leave No One Behind</p> <ul style="list-style-type: none"> <li>- Future intervention strategies for Influenza and COVID-19</li> <li>- How to integrate innovations into lifetime vaccination</li> <li>- HPV vaccination: Optimism for 2030</li> <li>- Integrative Vaccinology-Optimising vaccine schedules for children and adults</li> </ul>	<p><b>Chair:</b> <b>Albert Osterhaus (Germany)</b></p> <p>Robin Nandy (US)</p> <p>Marc Van Ranst (Belgium)</p> <p>Aimée R. Kreimer (US)</p> <p>Johannes Trück (Switzerland)</p>

Not yet registered? Register [here!](#)

**DAY 2, 28th April, 13:00 – 18:30 CEST (GMT+2 Belgium)**

Session	Duration	Session Description	Speakers
13:00-13:05	5min	Introduction	Mary Slack (UK)
13:05-13:20	15min	Bats: good or bad fortune? Questions for Lin-Fa Wang part 2	Lin – Fa Wang (Singapore) Philippe Buchy (Singapore)
13:20-14:20	60min	- Introduction Presentations followed by Q&A: 1. Overview of the technology platforms for vaccine development: established vaccines & new technologies 2. The contribution of rational vaccine immunogen design and structural vaccinology to current and future vaccines 3. COVID-19 vaccines using new technologies - Q&A	<b>Chair:</b> <b>Kanta Subbarao (Australia)</b> Barney Graham (US) Kathleen Neuzil (US)
14:20-14:30	10min	Transfer break	
14:30-16:00	90min	- Introduction Presentations followed by discussion/ Q&A: - Disease transmission and vaccination strategies – what have we learned? - COVID in children – to vaccinate or not? - Indirect effect of COVID on children – worse than direct effects? - Aspects on maternal immunization - Discussion/Q&A	<b>Chair:</b> <b>Mary Slack (UK)</b> Benjamin John Cowling (Hong Kong) Shamez Ladhani (UK) Catherine Weil-Olivier (France) Flor Muñoz (US)
16:00-16:20	20min	BREAK	
16:20-17:20	60min	Antimicrobial resistance as a medical need beyond COVID - 3 angles, in view on what can be done to prevent it The next pandemic: fail to prepare means prepare for failure Learnings from COVID 19 and future implications: - Surveillance systems - Disease epidemiology - Flexible design of clinical studies can facilitate development of future vaccines - Future vaccine priorities	<b>Chair:</b> <b>Johannes Liese (Germany)</b> Sally Davies (UK) Shabir Madhi (South Africa)
17:20-17:30	10min	Transfer break	

	Session	Duration	Session Description	Speakers
17:30-18:30	<p><b><u>Vaccine questions on your mind: ask the experts</u></b></p> 	60min	<p>- Introduction</p> <p>Panel discussion:</p> <p>- A panel of vaccine experts, including the event Scientific Committee, will respond to questions received from the audience</p>	<p><b>Moderator:</b> <b>Leonard Friedland</b></p> <p>Paolo Bonanni (Italy)</p> <p>Johannes Liese (Germany)</p> <p>Flor Muñoz (US)</p> <p>Malik Peiris (Hong Kong)</p> <p>Mary Slack (UK)</p> <p>LJ Tan (US)</p>

Not yet registered? Register [here!](#)

## Vaccine Virtual Days Scientific Committee and Speakers (alphabetical order)

### Scientific Committee

Name	Surname	Affiliation(s)	Country
Paolo	Bonanni	Professor of Hygiene in the School of Human Health Sciences and Director of the Department of Health Sciences, University of Florence	Italy
Emilie	Karafilakis	Research Lead at the Vaccine Confidence Project, London School of Hygiene & Tropical Medicine	UK
Johannes	Liese	Head of the Division of Pediatric Infectiology and Immunology, Department of Pediatrics, University Hospital of Würzburg	Germany
Flor	Muñoz	Associate Professor of Pediatrics and Infectious Diseases at Baylor College of Medicine Director of Transplant Infectious Diseases at Texas Children's Hospital, Houston, Texas	US
Malik	Peiris	Professor, Chair of Virology at the School of Public Health, University of Hong Kong, Division of Public Health Laboratory Sciences	Hong Kong
Mary	Slack	Independent Consultant at Mary Slack Microbiology Consulting Ltd and Professor at Griffith University School of Medicine, Australia	UK
Kanta	Subbarao	Director of the WHO Collaborating Centre for Reference and Research on Influenza	Australia
LJ	Tan	Chief Strategy Officer, Immunization Action Coalition & Co-Chair, National Adult and Influenza Immunization Summit	US

Not yet registered? Register [here!](#)

## Vaccine Virtual Days Speakers (alphabetical order)

### Speakers

Name	Surname	Affiliation(s)	Country
Nighat	Arif	RCGP, DRCOG DFSRH LoTiud NHS GP with a Specialist Interest in Womens Health COVID19 Vaccinator Resident GP on BBC 1 BBC Breakfast, BBC LookEast, ITV This Morning Host of the Sunday Breakfast Show on BBC Three Counties Radio	UK
Ran	Balicer	Founding Director, Clalit Research Institute Chief Innovation Officer, Director of Innovation Division Clalit Health Services, Professor, Public Health Department, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel	Israel
Jane	Barratt	Secretary General, International Federation on Ageing Member, Vision Academy, Director, Baycrest Health Sciences and Chair, Education Advisory Committee, Associate Scientist, Sinai Health System, Member, Global Committee, DR Barometer Program, Member, International Council for Adult Immunisation and Task, and CSO Representative, WHO COVAX Pillar “vaccine strategy” and Member of the European Interdisciplinary Council on Ageing Assembly	Canada
Rebecca	Christopher	Digital Campaigns Director, Purpose Campaigns	US
Benjamin John	Cowling	Professor Head of Division of Epidemiology and Biostatistics	Hong Kong
Barney	Graham	Deputy Director Vaccine Research Center , NIAID, NIH Chief Viral Pathogenesis Laboratory and Translational Science Core	US
Sally	Davies	UK Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge University	UK
Aimée R.	Kreimer	Senior Investigator, Infections & Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health	US
Shamez	Ladhani	Professor of Paediatric Infectious Diseases and Vaccinology, St George’s University of London	UK
Heidi	Larson	Professor of Anthropology , Risk and Decision Science; Director, The Vaccine Confidence Project, London School of Hygiene & Tropical Medicine	UK
Shabir	Madhi	Dean: Faculty of Health Sciences   University of the Witwatersrand, Johannesburg Professor of Vaccinology Director: Vaccines & Infectious Diseases Analytics Research Unit (Wits - VIDA) Co-Director: African Leadership in Vaccinology Expertise (ALIVE), South Africa	South Africa
Robin	Nandy	Principal Adviser and Chief of Immunization, Health Section, Programme Division, UNICEF Headquarters	US
Leyla	Namazova-Baranova	Head of the paediatric department in Pirogov Russian National Research Medical University, head of the Research Institute of Pediatrics and Child Health in the Central Clinical Hospital of the RAS, leading expert of preventive medicine in the MoH RF, chairman of NITAG RF, President of the Union of Pediatricians of Russia	Russia
Kathleen	Neuzil	Director of the Center for Vaccine Development and Global Health (CVD) and the Lead for the Division of Geographic Medicine at the University of Maryland School of Medicine.	US



Ayoade	Olatunbosun -Alakija	Co-Chair - Africa Union Africa Vaccine Delivery Alliance	Nigeria
Albert	Osterhaus	Director of the Center of Infection Medicine and Zoonosis Research at the University of Veterinary Medicine Hannover, Germany, CSO Viroclinics-DDL & CR2O (spin-out companies), Ad-hoc advisor and SAB member pharmaceutical companies	Germany
Mitchel	Rothholz	Chief of Governance & State Affiliates and Executive Director, APhA Foundation, American Pharmacists Association	US
John	Tam	Visiting Professor at the Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University Director and Chairman Asia-Pacific Alliance for the Control of Influenza	Hong Kong
Johannes	Trück	Consultant, Division of Immunology, Group leader, Children's Research Center, University Children's Hospital Zurich, University of Zurich (UZH), Switzerland	Switzerland
Marc	Van Ranst	Professor of Virology and Epidemiology Chairman, department of Microbiology, Immunology and Transplantation Director Clinical and Epidemiological Virology Unit Head of the Laboratory Medicine Department University Hospitals Leuven, Belgium	Belgium
Lin-Fa	Wang	Professor, Programme in Emerging Infectious Diseases at Duke-NUS Medical School, Singapore	Singapore
Catherine	Weil-Olivier	Independent expert in vaccines, vaccinations and influenza	France
Sanne	Wendes	Gavi, the Vaccine Alliance, Lead Design and Operationalisation in the Office of the Covax Facility	Switzerland

This event has been organised and funded by GSK and is intended for Healthcare Professionals only.

Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products [adversedrugreactions@afmps.be](mailto:adversedrugreactions@afmps.be) or via the 'yellow card' available on <https://www.famhp.be/en> or to GlaxoSmithKline Pharmaceuticals s.a/n.v. 010/85 85 00.

For other countries, to report adverse events, details can be found at: <https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/>

© 2021 GSK group of companies or its licensor. GlaxoSmithKline Biologicals SA. Rixensart, Belgium

<https://be.gsk.com/en/>

[Privacy Notice](#) | [Terms of Use](#)

April 2021 | NX-GBL-GVX-AGND-210002

#### **Privacy Notice Summary**

GSK ensures any data you provide is held securely. We will use your data to register you for the event and get your feedback on the quality of the sessions. We will share registrant and attendance information with GSK staff organising the event in your country.